Company profile
Cue Biopharma, Inc.
NASDAQ: CUE · Healthcare · Biotechnology
#516 of 1,418 Healthcare companies by revenuetop-quartile growth
EA Score
49DFH 42DQ 51GM 69SS 49
v0.1 · 65/100 weight · provisional
↑ 3-yr revenue growth, revenue growth (YoY) · ↓ Piotroski F, growth stability
Methodology →Revenue TTM
$37.7M
Rev growth YoY (TTM)
+354.4%
Net income (FY)
-$26.6M
Employees
29
as of 2026-08-18
Market cap
$67.2M
as of 2026-08-18
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$27.5M$27.5M2025
Net income-$26.6M-$26.6M2025
Operating income-$26.6M-$26.6M2025
Total assets$42.2M$42.2M2025
Liabilities$15.8M$15.8M2025
Equity$26.4M$26.4M2025
Revenue trend
FY2018 – FY2025 · USD
FY18
FY19
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Cue Biopharma, Inc.’s revenue?
Cue Biopharma, Inc. booked $27.5M in FY2025 revenue, growing 196% year over year — faster than most Healthcare companies we track, at a -96.9% net margin.
Peers · Healthcare
American Shared Hospital Services59CImmuCell Corporation63CSensus Healthcare, Inc.51DINNOCAN PHARMA Corp59CCelularity Inc.31DNeurobiological Technologies, Inc.——Neighbors
Suffolk →Key facts
CEOShao-Lee Lin
SectorHealthcare
IndustryBiotechnology
HeadquartersBoston, MA
ExchangeNASDAQ: CUE
Employees29
IPO date2018-01-02
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.